Related Experiment Video
Updated: Nov 21, 2025
07:37
Mouse Models for Graft Arteriosclerosis
Published on: May 14, 2013
13.9K
Guidelines for mono, double and triple antithrombotic therapy.
Renate C A E van Uden1,2, Ilse Houtenbos3, Anita Griffioen-Keijzer3
1Hospital Pharmacy, Spaarne Gasthuis, Haarlem, Noord-Holland, Netherlands.
Postgraduate Medical Journal
|January 14, 2021
Summary
Managing antithrombotic therapy requires careful consideration of multiple indications. This overview simplifies complex guidelines, advising against lifelong dual or triple therapy for patients needing antithrombotic treatment.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Antithrombotic therapy guidelines are complex, particularly for patients with multiple indications.
- Lifelong dual or triple antithrombotic therapy is generally not recommended.
Purpose of the Study:
- To provide an overview of antithrombotic therapy guidelines.
- To outline common indications for mono, double, and triple antithrombotic therapy.
- To specify preferred therapies and recommended durations.
Main Methods:
- Review of European and Dutch guidelines for antithrombotic therapy.
- Inclusion of antiplatelet agents and therapeutic anticoagulation (vitamin K antagonists, direct oral anticoagulants).
Main Results:
- Detailed indications for various antithrombotic regimens (mono, double, triple therapy).
- Recommendations on preferred antithrombotic agents and treatment durations.
- Emphasis on avoiding prolonged dual or triple antithrombotic therapy.
Conclusions:
- Simplifies complex antithrombotic therapy decision-making.
- Provides clear guidance on appropriate use and duration of antiplatelet and anticoagulant therapies.
- Aims to improve patient outcomes by optimizing antithrombotic treatment strategies.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
115
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
115
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
01:26Atherosclerosis III: Management
131
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
131
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
865
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
865
01:27Coronary Artery Disease V: Interprofessional Care
125
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
125